Sharma @Amansharmapgi et al. DADA2. Clinical manifestations of 101(!) patients. @RheumNow #ACR24 Abstr#2647 https://t.co/Tkk6Rz6rtT https://t.co/frvFPYy4xf

• Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a …
• https://x.com/RichardPAConway/status/1858603584356774002/photo/1

Medeiros-Ribeiro et al. Holding MTX for 2 weeks after recombinant zoster vaccine increases response with no increase in flare. @RheumNow #ACR24 Abstr#2612 https://t.co/NEop0XB5Ak https://t.co/P4S2qzbkTs

• Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients…
• https://x.com/RichardPAConway/status/1858606100754407799/photo/1

SmPCs recommend interrupting immunosuppression (IS) in infection What happens if you continue the drug? Ab2611 found no difference in infection outcomes btwn temp interruption & continuation of IS in infection Could continuation be a safe option in some pts? #ACR24 @RheumNow https://t.co/14SN6a4Wm8

• https://x.com/DrMiniDey/status/1858606604293468406/photo/1

Evaluation of Bimekizumab in PsA At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2… https://t.co/lphZUiiq5T https://t.co/zuHpBaMtEv

Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR

• Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomi…
• https://x.com/RichardPAConway/status/1858572630426874065/photo/1

#2286🔬Certolizumab Pegol (CZP) in High RF RA 📊Pooled analysis;N=1180 💥PBO: High RF=more radiographic progression v low RF (Wk24 6.5 v 2.8%,Wk52 17.6 v 10.4%) 💥CZP: min. progression regardless of RF (Wk24 0 v 1.1%;Wk52 5.3 v 3.1%) #ACR24 @RheumNow https://t.co/koel7SDsUb

• https://x.com/CaoilfhionnMD/status/1858548471554605138/photo/1

Triboulet et al. JAKi in RA-ILD. 42 patients. Stability of PFTs over median 21 months. HRCT stable in 62%. Progressive ILD on HRCT in 19%. @RheumNow #ACR24 Abstr#2249 https://t.co/PY9BrCfNHc https://t.co/r8fIgrjyDu

• Assessment of Interstitial Lung Disease in Rheumatoid Arthritis Patients Treate…
• https://x.com/RichardPAConway/status/1858548723107668184/photo/1

Tesser et al. Implanted cervical vagus nerve stimulator for b/tsDMARD-IR RA. 242 patients. ACR20 week 12 35% vs 24%. Higher rates of DAS28-CRP LDA/remission. @RheumNow #ACR24 Abstr#L10 https://t.co/OXojHEMkKQ https://t.co/XSt97u7LrR

• Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Respo…
• https://x.com/RichardPAConway/status/1858549226499645467/photo/1

@DianeLacaille Canadian biosimilar exp Biosimilar transition v originator controls x2 yrs Weighted model: no decr in ETN biosimilar discontinuation v originator. IFX shows slight decrease - NOT statistical signif Safety- no difference, slight incr rheum visits @RheumNow #ACR24 https://t.co/0GMfLAyzOo

• https://x.com/ericdeinmd/status/1858542595636392007/photo/1

Galloway et al. 117,050 individuals. VTE risk in RA consistently increased, irrespective of age, sex, BMI. Risk VTE 46% higher in RA! @RheumNow #ACR24 Abstr#1901 https://t.co/SQPcPiBeF2 https://t.co/BQkERUsGlL

• Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid…
• https://x.com/RichardPAConway/status/1858545954540175534/photo/1

Abstract 1842: Off the shelf CAR T therapy No lymphodepletion needed, delivering robust, targeted CD19+ B cell elimination in multiple in vitro assays @RheumNow #ACR24